데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
23152-29-6CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=OFEPMHVLSLDOMQC-IYPFLVAKSA-N23152-29-6DTXSID0046856CHEMBL1236684CHEBI:46416안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
용도Virginiamycin complex is defined as a mixture of 75% ostreogrycin A (virginamycin M1) and 25% virginiamycin S1, together with the less abundant S analogues. As the two major components have quite different solubilities, these proportions are not readily achieved or used. BioAustralis has isolated and re-combined the individual components to provide the defined components of virginiamycin complex. The composition of the complex is important as Virginiamycin S1 acts a synergist, binding to the conformational change of the peptidyl transferase centre of the 50S ribosome induced by ostreogrycin A.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…